

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Long term physical and mental sequelae of COVID-19, tixagevimab–cilgavimab for prevention, natural and hybrid immunity to SARS-CoV-2

Peer reviewed journals featured:

- Systematic reviews on:
 - Long term physical and mental sequelae of COVID-19 [here](#)
 - Prevalence of and risk factors associated with depression, anxiety and insomnia in infectious diseases, including COVID-19 [here](#)
- Randomised clinical trials of:
 - Intramuscular tixagevimab–cilgavimab for preventing COVID-19 [here](#) and [here](#)
 - The effect of molnupiravir on biomarkers, respiratory interventions, and services [here](#)
- Narrative reviews on:
 - Effects of maternal SARS-CoV-2 infection on the offspring's nervous system [here](#)
 - Advances in the management of inflammatory bowel disease during COVID-19 [here](#)
- Observational studies on:
 - Protection and waning of natural and hybrid immunity to SARS-CoV-2 [here](#)
 - Associations between reductions in routine care delivery and non-COVID-19-related mortality in people with diabetes in England [here](#) and associated commentary [here](#)
 - Changes in SARS-CoV-2 antibody levels over time [here](#)
 - Association of COVID-19 vaccination during pregnancy and SARS-CoV-2 infection in infants in Norway [here](#)
 - Clinical outcomes associated with Omicron and BA.1/BA.1.1 or BA.2 subvariant infections in southern California [here](#)
 - Duration of mRNA vaccine protection against Omicron BA.1 and BA.2 in Qatar [here](#)
 - Ventilation improvement strategies among K–12 public schools [here](#)
- A modelling study on the impact of non-pharmaceutical interventions and vaccination on COVID-19 trajectories [here](#)
- An editorial on physical activity for children following the disruptions of COVID-19 in Australia [here](#)
- Commentary on reducing SARS-CoV-2 in shared indoor air [here](#)

Letters and correspondence discussed:

- Effectiveness of mRNA vaccines against Omicron in South Africa [here](#)
- Serum neutralisation of Omicron BA.1 and BA.2 after Comirnaty (Pfizer) booster [here](#)
- Endoscopy volumes and outcomes at a tertiary Melbourne centre during the 2020 lockdowns [here](#)
- Sotrovimab drives Omicron variant evolution in immunocompromised patients [here](#)
- Association between COVID-19 booster and Omicron infection in NBA players and staff [here](#)
- COVID-19 highlights the need for action on pulse oximeter accuracy in people with dark skin [here](#)

Pre-peer review articles featured:

- Persistence of immunity against Omicron BA.1 and BA.2 after homologous and heterologous boosters [here](#)
- Non-pharmacological therapies for post-viral syndromes, including long COVID [here](#)

Guidance and reports

- The World Health Organization published updates on its:
 - Recommendations for the use of the Johnson & Johnson-Janssen vaccine [here](#)
 - COVID-19 epidemiological report [here](#), and the landscape of observational studies on the effectiveness of COVID-19 vaccination [here](#)
- The Australian Technical Advisory Group on Immunisation (ATAGI) recommendations on first booster dose in adolescents aged 12-15 years [here](#)
- The National COVID-19 Clinical Evidence Taskforce released updated recommendations and clinical flowcharts [here](#)

[Click here](#) to subscribe to, or unsubscribe from, the evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(long COVID\)](#), [surgery and COVID-19](#), and [rapid testing](#).